Cipla: Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Read full article »
Cipla develops and produces drugs for the treatment of arthritis, diabetes, weight control, depression and cardiovascular diseases.
Read more